Fusion Pharmaceuticals (FUSN)
(Delayed Data from NSDQ)
$21.52 USD
+0.05 (0.23%)
Updated May 31, 2024 04:00 PM ET
After-Market: $21.54 +0.02 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FUSN 21.52 +0.05(0.23%)
Will FUSN be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for FUSN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FUSN
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates
Fusion Pharmaceuticals Inc. (FUSN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
FUSN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect
Fusion Pharmaceuticals Inc. (FUSN) Ascends But Remains Behind Market: Some Facts to Note
AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect
Other News for FUSN
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement
Ontario court approves AstraZeneca/Fusion acquisition plan
Fusion Pharmaceuticals receives final court order approving AstraZeneca deal
Fusion Pharmaceuticals Shareholders Back Major AstraZenica Deal
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca